Clinical Trial Update: Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) [Phase 1]

View source ↗

Summary

Phase 1 trial of ADCT-301 in relapsed/refractory CD25-positive AML or CD25-positive ALL was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia

Drugs mentioned

• ADCT-301 (camidanlumab tesirine)

Snippet

Sponsor: ADC Therapeutics S.A. | Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Status: TERMINATED | Results posted: 2020-02-26